(VIANEWS) – A fourth wave of Covid could soon be on the horizon. This delta variant has been the most difficult to combat since the widespread availability of coronavirus vaccinations. The rapid transmission of the virus is outmatched only by its ability to change shape into the delta-plus version. With the distribution of 200,000,000 doses, NVAX shares are on the rise.
InvestorPlace confirmed that the U.S. government has begun to respond with President Joe Biden setting some strict vaccination guidelines for federal workers suggesting they should get vaccinated, or be subject to frequent testing. Cities are now required to show proof of vaccination in order to dine out or use public gyms. New York is the first to start this trend.
Shares of Novavax (NVAX) jumped 6.35% to $238.03 at 11:26 EST on Thursday, after two successive sessions in a row of gains. NASDAQ Composite is jumping 0.65% to $14,877.32, after three consecutive sessions in a row of gains. This seems, up to now, a somewhat bullish trend exchanging session today.
Novavax’s last close was $188.57, 43.15% under its 52-week high of $331.68.
Today’s last reported volume for Novavax is 4696963 which is 11.89% above its average volume of 4197770.
The company’s growth estimates for the current quarter is a negative 1110% and positive 12.1% for the next.
Year-on-year quarterly revenue growth grew by 13143.4%, now sitting on 919.45M for the twelve trailing months.
Novavax’s last week, last month’s, and last quarter’s current volatility was a negative 2.70%, a negative 0.54%, and a positive 4.42%, respectively.
Novavax’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 5.50% (last week), 3.61% (last month), and 4.42% (last quarter), respectively.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,
Novavax’s stock is considered to be oversold (<=20).
Novavax’s Stock Yearly Top and Bottom Value
Novavax’s stock is valued at $238.03 at 11:26 EST, way below its 52-week high of $331.68 and way higher than its 52-week low of $76.59.
Novavax’s Moving Average
Novavax’s worth is way above its 50-day moving average of $192.99 and way above its 200-day moving average of $196.62.
More news about Novavax (NVAX).